{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:54:37Z","timestamp":1777618477471,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>\n                    To evaluate the efficacy, safety, and tolerability of switching to a dolutegravir (DTG)-based regimen in a cohort of virological suppressed HIV-infected patients who have previously been treated with different antiretroviral combination. The dynamics of total HIV-DNA and levels of high-sensitivity c-reactive protein, interleukin-6, soluble-CD14, and D-Dimer were also analyzed. Ninety-six individuals who switched to a DTG-containing regimen were followed up for 48 weeks. HIV RNA, CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell count, weight, and levels of laboratory parameters were recorded at baseline, after 24 and 48 weeks of treatment for all study participants. In a subgroup of patients, HIV DNA and inflammation\/coagulation marker levels were also analyzed until week 24. Ninety-three out of 96 patients maintained virological suppression, including patients who switched to dual-therapy from triple-drug combination. Eighteen out of 96 patients had residual viremia at baseline, of which 13 reached the maximal viral suppression at W48. Serum creatinine levels showed a significant increase at weeks 24 and 48. A progressive reduction of total cholesterol was observed from week 24 and up to week 48. No variation in body mass index was detected. HIV DNA, inflammation, and coagulation marker levels did not significantly change during follow-up. Switching to a DTG-based regimen may be a key option for achieving and maintaining maximal virological suppression, even in patients showing residual viremia at baseline. Furthermore, the improvement in blood lipid profile and the overall tolerability observed in this study strongly support the use of these regimens in the aging HIV population.\n                  <\/jats:p>","DOI":"10.1089\/aid.2020.0196","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:31:21Z","timestamp":1611534681000},"page":"478-485","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting"],"prefix":"10.1177","volume":"37","author":[{"given":"Daniele","family":"Di Carlo","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Falasca","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Palermo","sequence":"additional","affiliation":[{"name":"Istituto Pasteur-Fondazione Cenci Bolognetti, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivano","family":"Mezzaroma","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Fimiani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Umberto I University Hospital, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Siccardi","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Celani","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Maria","family":"Di Campli","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"d'Ettorre","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ombretta","family":"Turriziani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Rome Sapienza, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.10958"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/8394"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12814"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-016-0105-z"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix202"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/381450"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0588-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0201-6"},{"key":"e_1_3_3_10_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with Hiv. Department of health and human services. Updated December 18 2019. Available at www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf accessed December20 2019."},{"key":"e_1_3_3_11_2","unstructured":"EACS Guidelines Version 9.0. Updated October 2017. Available at www.eacsociety.org\/files\/guidelines_9.0-english.pdf accessed December20 2019."},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Blanco J-L Martinez-Picado J: HIV integrase inhibitors in ART-experienced patients: Curr Opin HIV AIDS 2012;7:415\u2013421.","DOI":"10.1097\/COH.0b013e328356dcb6"},{"key":"e_1_3_3_13_2","first-page":"29","article-title":"Potential benefit of dolutegravir once daily: Efficacy and safety","volume":"5","author":"Fantauzzi A","year":"2013","unstructured":"Fantauzzi A, , Turriziani O, , Mezzaroma I: Potential benefit of dolutegravir once daily: Efficacy and safety. HIV, 2013; 5:29\u201340.","journal-title":"HIV"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622314530461"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3166"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Mazzuti L Mezzaroma I Falasca F Turriziani O: Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors: AIDS 2017;31:1900\u20131901.","DOI":"10.1097\/QAD.0000000000001581"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky467"},{"key":"e_1_3_3_21_2","unstructured":"van Wyk J Ajana F Bisshop F et al.: Switching to DTG +3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study). In: 10th IAS Conference on HIV Science. Mexico City Mexico. July 2019. Abstract 4903."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2311-2"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12611"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"de Boer MGJ van den Berk GEL van Holten N et al.: Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice: AIDS 2016;30:2831\u20132834.","DOI":"10.1097\/QAD.0000000000001279"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001459"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25227"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12688"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001351"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2019.1628460"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3666-8"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210476"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2755-4"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000414"},{"key":"e_1_3_3_35_2","first-page":"448","article-title":"Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients","volume":"15","author":"Bon I","year":"2017","unstructured":"Bon I, , Calza L, , Musumeci G, et al.: Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. Curr HIV Res, 2017; 15:448\u2013455.","journal-title":"Curr HIV Res"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.03.018"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa058"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu585"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-017-0355-y"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2676-2"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw650"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525"},{"key":"e_1_3_3_43_2","unstructured":"Mugglin C Calmy A Gunthard H et al.: Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV cohort study. In: 17th European AIDS Conference. Basel Switzerland November 2019."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1386"},{"key":"e_1_3_3_45_2","first-page":"211","article-title":"Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs","volume":"35","author":"Quercia R","year":"2015","unstructured":"Quercia R, , Roberts J, , Martin-Carpenter L, , Zala C: Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig, 2015; 35:211\u2013219.","journal-title":"efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","unstructured":"Gatell JM Assoumou L Moyle G et al.: Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk: AIDS 2017;31:2503\u20132514.","DOI":"10.1097\/QAD.0000000000001675"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S203813"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2020.0196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2020.0196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:16:00Z","timestamp":1777367760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2020.0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1089\/aid.2020.0196"],"URL":"https:\/\/doi.org\/10.1089\/aid.2020.0196","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}